Vitamin D, immunoregulation, and rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 17, Issue 2, 2011, Pages 102-107

  Wen, Hongyan ^a,b,c   Baker, Joshua F ^b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

immunoregulation; rheumatoid arthritis; vitamin D

Indexed keywords

ALFACALCIDOL; INTERLEUKIN 4; INTERLEUKIN 6; VITAMIN D; VITAMIN D RECEPTOR;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CALCIUM ABSORPTION; CD4+ T LYMPHOCYTE; CHONDROLYSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOREGULATION; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; TH17 CELL; VITAMIN D DEFICIENCY; VITAMIN INTAKE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HEMOSTASIS; HUMANS; IMMUNE SYSTEM; TREATMENT OUTCOME; VITAMIN D;

EID: 79952405704     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31820edd18     Document Type: Review

References (78)

1. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutrition. 2004;6:1678S-1688S.
2. Bringhurst FR, Demay MB, Kronenberg HM. Hormones and disorders ofmineral metabolism. In: Kronenberg HM, Melmed S, Polonsky KS, et al, eds. Williams Textbook ofEndocrinology. 11 ed. Philadelphia: Elsevier; 2008.
3. May E, Asadullah K, Zugel U. Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy. 2004;3:377-393. (Pubitemid 39534774)
4. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new etiological and therapeutical considerations. Ann Rheum Dis. 2007;66:1137-1142. (Pubitemid 47309727)
5. Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 2004;50:72-77. (Pubitemid 38084289)
6. Cutolo M, Otsa K, Laas K, et al. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: northern versus southern Europe. Clin Exp Rheumatol. 2006;24:702-704. (Pubitemid 46138805)
7. Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97:93-101.
8. Mahon BD, Wittke A, Weaver V, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem. 2003;89:922-932. (Pubitemid 36927724)
9. Bhalla AK, Amento EP, Serog B, et al. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol. 1984;133: 1748-1754. (Pubitemid 14035260)
10. Lemire JM. Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem. 1992;49:26-31.
11. Mattner F, Smiroldo S, Galbiati F, et al. Inhibition of Th1 development and treatment ofchronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol. 2000;30:498-508. (Pubitemid 30098842)
12. + T cells to enhance the development of Th2 cells. J Immunol. 2001;167:4974-4980. (Pubitemid 33009728)
13. Cippitelli M, Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol. 1998;28:3017-3030. (Pubitemid 28470247)
14. Cantorna M, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med. 2004;229:1136-1142. (Pubitemid 39602256)
15. Adorini L. Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis. JChemother. 2001;13:219-234. (Pubitemid 32575133)
16. Overbergh L, Decallonne B, Waer M, et al. 1α,25-Dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes. 2000;49:1301-1307. (Pubitemid 30624229)
17. Cantorna MT, Woodward WD, Hayes CE, et al. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 andIL-4. J Immunol. 1998;160:5314-5319. (Pubitemid 28267819)
18. + T cells. J Immunol. 2000;168:1181-1189. (Pubitemid 34094483)
19. Tobler A, Gasson J, Reichel H, et al. Granulocyte-macrophage colony-stimulating factor. Sensitive and receptor-mediated regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral blood lymphocytes, J Clin Invest. 1987;79:1700-1705. (Pubitemid 17117276)
20. Xue ML, Zhu H, Thakur A, et al. 1α,25-Dihydroxyvitamin D3 inhibits pro-inflammatory cytokine and chemokine expression in human corneal epithelial cells colonized with Pseudomonas aeruginosa. Immunol Cell Biol. 2002;80:340-345. (Pubitemid 34779691)
21. Stockinger B. Th17 cells: an orphan with influence. Immunol Cell Biol. 2007;85:83-84. (Pubitemid 46398729)
22. Cippitelli M, Fionda C, Di Bona D, et al. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J Immunol. 2002;168:1154-1166. (Pubitemid 34094480)
23. Heine G, Anton K, Henz BM, et al. 1α,25-Dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. Eur JImmunol. 2002;32:3395-3404. (Pubitemid 36024377)
24. Linker-Israeli M, Elstner E, Klinenberg JR, et al. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol. 2001;99:82-93.
25. Muller K, Heilmann C, Poulsen LK, et al. The role ofmonocytes and T cells in 1,25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. Immunopharmacology. 1991;21:121-128.
26. Provvedini DM, Tsoukas CD, Deftos LJ, et al. 1α, 25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol. 1986;136:2734-2740. (Pubitemid 16107171)
27. Iho S, Takahashi T, Kura F, et al. The effect of 1,25-dihydroxyvitamin D3 on in vitro immunoglobulin production in human B cells. J Immunol. 1986;136:4427-4731.
28. Deluca HF, Cantorna M. Vitamin D: its role and uses in immunology. FASEBJ. 2001;15:2579-2585. (Pubitemid 33131084)
29. Berer A, Stockl J, Majdic O, et al. 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol. 2000;28:575-583. (Pubitemid 30254459)
30. Penna G, Adorini L. 1α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival ofdendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164:2405-2411. (Pubitemid 30115468)
31. Griffin MD, Lutz WH, Phan VA, et al. Potent inhibition ofdendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 2000;270:701-708. (Pubitemid 30444768)
32. Helming L, Bose J, Ehrchen J, et al. 1α,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood. 2005;106:4351-4358. (Pubitemid 41775947)
33. Kiran G, Debashish D. Vitamin D and rheumatoid arthritis: is there a link? Int J Rheum Dis. 2008;11:206-211.
34. Harris ED Jr, Schur PH. Pathogenesis of rheumatoid arthritis. In: Basow, DS ed. Up To Date. Waltham, MA: Up To Date; 2007.
35. Cutolo M, Otsa K. Vitamin D, immunity and lupus. Lupus. 2008;17:6-10.
36. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol. 2004;89-90:611-614. (Pubitemid 38844358)
37. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223:230-233. (Pubitemid 30337776)
38. Tetlow LC, Smith SJ, Mawer EB, et al. Vitamin D receptors in the rheumatoid lesion: expression by chondrocytes, macrophages, and synoviocytes. Ann Rheum Dis. 1999;58:118-121. (Pubitemid 29116313)
39. Tetlow LC, Wooley DE. The effects of 1α,25-dihydroxyvitamin D3 on matrix metalloproteinase and prostaglandin E2 production by cells of the rheumatoid lesion. Arthritis Res. 1999;1:63-70. (Pubitemid 32223674)
40. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662-687. (Pubitemid 41127276)
41. Manolagas SC, Werntz DA, Tsoukas CD, et al. 1,25-Dihydroxyvitamin D3 receptors in lymphocytes from patients with rheumatoid arthritis. JLab Clin Med. 1986;108:596-600. (Pubitemid 17186613)
42. Gomez-Vaquero C, Fiter J, Enjuanes A, et al. Influence of the Bsml polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity. J Rheumatol. 2007;34:1823-1826. (Pubitemid 350067640)
43. Nagpal S, Lu JF, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem. 2001;8: 1661-1679. (Pubitemid 33076807)
44. Aguado P, del Campo MT, Garces MV, et al. Low vitamin D levels in outpatient postmenopausal women from a rheumatology clinic in Madrid, Spain: their relationship with bone mineral density. Osteoporosis Int. 2001;11:739-744.
45. Craig SM, Yu F, Curtis JR, et al. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol. 2010;37: 275-281.
46. Als OS, Rils B, Christiansen C. Serum concentration of vitamin D metabolites in rheumatoid arthritis. Clin Rheumatol. 1987;6:238-243. (Pubitemid 17138674)
47. Leventis P, Patel S. Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology. 2008;47:1617-1621.
48. Moscovici YB, Toledano K, Markovits D, et al. Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatol Int. 2009;11:28.doi:10.1007/s00296-009-1251-6.
49. Costenbader KH, Feskanich D, Holmes M, et al. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis. 2008;67:530-535. (Pubitemid 351498436)
50. Nielen MM, van Schaardenburg D, Lems WF, et al. Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al [letter]. Arthritis Rheum. 2006;54: 3719-3720. (Pubitemid 44737186)
51. Marques C, Dantas A, Fragoso T, et al. The importance of vitamin D levels in autoimmune diseases. Bras J Rheumatol. 2010;50:73-80.
52. Iikuni N, Nakajima A, Inoue E, et al. What's in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity. Rheumatology. 2007;46:846-848. (Pubitemid 47061720)
53. Patel S, Farragragher T, Berry J, et al. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 2007;56:2143-2149. (Pubitemid 47173561)
54. Kroger H, Pentilla IM, Alhava EM. Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand J Rheumatol. 1993;22: 172-177. (Pubitemid 23233552)
55. Cutolo M, Otsa K, Yprus M, et al. Vitamin D and rheumatoid arthritis: comment on the letter by Nielen et al [letter]. Arthritis Rheum. 2007;56:1719-1720. (Pubitemid 46764104)
56. Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:745-747.
57. Andjelkovic Z, Vojinovic J, Pejnovic N, et al. Disease modifying and immunomodulatory effects ofhigh dose 1a(OH)D3 in rheumatoid arthritispatients. Clin Exp Rheumatol. 1999;17:453-456. (Pubitemid 29343630)
58. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine. 2007;41:84-91.
59. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. JExp Med. 2007;204:1849-1861. (Pubitemid 47240944)
60. Aarvak T, Chabaud M, Miossec P, et al. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol. 1999;162:1246-1251. (Pubitemid 29306992)
61. Aarvak T, Chabaud M, Kallberg E, et al. Change in the Th1/Th2 phenotype ofmemory T-cell clones from rheumatoid arthritis synovium. Scand J Immunol. 1999;50:1-9. (Pubitemid 29298019)
62. Kroenke MA, Carlson TJ, Andjelkovic AV, et al. IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med. 2008;205:1535-1541. (Pubitemid 351962016)
63. Kirkham BW, Lassere MN, Edmonds JP, et al. Synovial membrane cytokine expression is predictive ofjoint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006;54:1122-1131. (Pubitemid 43672925)
64. Szodoray P, Nakken B, Gaal J, et al. The complex role of vitamin D in autoimmune diseases. Scand J Immunol. 2008;68:261-269.
65. Walsh NC, Crotti TN, Goldring SR, et al. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev. 2005;208:228-251. (Pubitemid 41746396)
66. Stewart A, Mackenzie LM, Black AJ, et al. Predicting erosive disease in rheumatoid arthritis. A longitudinal study ofchanges in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology (Oxford). 2004;43:1561-1564. (Pubitemid 39642583)
67. Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management ofcorticosteroid-induced osteoporosis: a meta-regression. JBone Miner Res. 2002;17: 1512-1526. (Pubitemid 34803834)
68. Evans HG, Suddason T, Jackson I, et al. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci USA. 2007;104:17034-17039. (Pubitemid 350210986)
69. Bettelli E, Korn T, Oukka M, et al. Induction and effector functions ofT(H)17 cells. Nature. 2008;453:1051-1057. (Pubitemid 351871737)
70. McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 2008;28:445-453. (Pubitemid 351467042)
71. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233-240. (Pubitemid 40189432)
72. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression ofantimicrobial peptides. JExp Med. 2006;203: 2271-2279. (Pubitemid 44498362)
73. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-ß, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9:650-657. (Pubitemid 351712635)
74. Lubberts E, Joosten LA, Chabaud M, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest. 2000;105:1697-1710. (Pubitemid 30421751)
75. 3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 2010;62:132-142.
76. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis.JNutr. 1998;128:68-72. (Pubitemid 28087178)
77. Jones BJ, Twomey PJ. Issues with vitamin D in routine clinical practice. Rheumatology. 2008;47:1267-1268.
78. Tsuji M, Fujii K, Nakano T, et al. 1a-Hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBSLett. 1994;337: 248-250.